Fosun Pharma (600196.SH): Plans to establish a private equity investment fund and prepare for the transfer of 100% equity of Shanghai Clone.

Zhimedia Financial News App, Fosun Pharma (600196.SH) announced that, in order to further focus on its core business and enhance asset operation efficiency, its holding subsidiary Fosun Pharma Industry plans to transfer 100% equity of Shanghai Clone (with its main asset being the property located at 1289 Yishan Road, Xuhui District, Shanghai). The steps and structure of this transaction are as follows: 1. Fosun Pharma Industry, as the LP cash investor, intends to invest RMB 54.6 million together with Hongyi Tianjin and China Life to establish a special fund (i.e. this investment), expecting to hold 9.98% of the property shares of the fund after it is fully raised; 2. After the establishment of the special fund and meeting the agreed conditions, Fosun Pharma Industry plans to transfer its 100% equity and debt rights of Shanghai Clone (i.e. this transfer) to the special fund or its controlled entity for no more than RMB 1.256 billion.